Skip to main content

2025 IDWeek Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Session Icons

Live Streamed

On Demand

Pablo Tebas, MD

MD
University of Pennsylvania

Disclosure(s): Merck: Honoraria; Shionogi: Honoraria; Viiv: Honoraria

Poster(s):

(P-377) Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1

Monday, October 20, 2025
12:15 PM - 1:30 PM US ET